Search our Database of Scientific Publications and Authors

I’m looking for a

    11116 results match your criteria Bone Marrow Transplantation[Journal]

    1 OF 223

    Foxp3 expression in induced T regulatory cells derived from human umbilical cord blood vs. adult peripheral blood.
    Bone Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Cleveland Cord Blood Center, Cleveland, OH, USA.
    Foxp3 is essential for T regulatory cell (Treg) function. Broad complex-Tramtrack-Bric-a-brac domain (BTB) and Cap'n'collar (CNC) homology 1, transcription factor 2 (BACH2) stabilizes Treg immune homeostasis in murine studies. However, little is known regarding what role, if any, BACH2 may have in Foxp3 regulation in human-induced Treg (iTreg). Read More


    High-dose chemotherapy and autotransplants for plasma cell myeloma in Jordan.
    Bone Marrow Transplant 2018 May 8. Epub 2018 May 8.
    Bone Marrow Transplantation Unit, Department of Internal Medicine, King Hussein Cancer Center, P.O. Box 1269 Al-Jubeiha, Amman, 11941, Jordan.


    Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease.
    Bone Marrow Transplant 2018 May 8. Epub 2018 May 8.
    Department of Hematology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, CopenhagenØ, 2100, Denmark.
    Improvement in chronic graft vs. host disease (cGvHD) following treatment with extracorporeal photopheresis (ECP) has been shown previously. However, the effect is often measured at only one point in time or as best response. Read More

    Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone Marrow Transplant 2018 May 4. Epub 2018 May 4.
    EBMT Chronic Malignancies Working Party, Leiden, Netherlands.
    The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. Read More

    Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.
    Bone Marrow Transplant 2018 May 4. Epub 2018 May 4.
    Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regiments, most patients had residual myeloma cells in their autologous stem-cell grafts during collection. Read More

    Circulating monocyte subsets in human chronic graft-versus-host disease.
    Bone Marrow Transplant 2018 May 4. Epub 2018 May 4.
    Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
    Chronic graft-versus-host disease (cGVHD) is a major cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Monocytes/macrophages play a central role in inflammation, tissue repair, and fibrosis, which are the main clinical features of cGVHD. Here, we examined the expression levels of activation markers, chemokine receptors, and scavenger receptors for each circulating monocyte subset in 145 patients without disease recurrence at least 12 months after undergoing allogeneic HCT. Read More


    Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility.
    Bone Marrow Transplant 2018 May 4. Epub 2018 May 4.
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.
    Current projections estimate that the number of newborns with sickle cell disease (SCD) globally will exceed 400,000 by 2050. Over the last three decades, increased newborn screening, supportive care, and use of hydroxyurea therapy, have decreased early childhood mortality among individuals affected with SCD. Despite hematopoietic cell transplantation (HCT) being curative in SCD, its impact on disease free survival remains unknown, especially in adults, partly due to previous limitations in donor options and perceived mortality in adults using myeloablative conditioning. Read More


    Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation.
    Bone Marrow Transplant 2018 May 2. Epub 2018 May 2.
    Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
    Hematopoietic cell transplantation (HCT) is increasingly used worldwide. This treatment approach is complex and requires specific knowledge and training. The European Society for Blood and Marrow Transplantation (EBMT) identified the need for a set of international recommendations for the clinical training of physicians to qualify them as being competent in performing HCT procedures as well as novel cellular immune therapies and taking care of such patients. Read More

    Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation.
    Bone Marrow Transplant 2018 May 2. Epub 2018 May 2.
    Dept. of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
    Conventional analysis of host chimerism (HC) frequently fails to detect relapse before its clinical manifestation in patients with hematological malignancies after allogeneic stem cell transplantation (allo-SCT). Quantitative PCR (qPCR)-based highly-sensitive chimerism analysis extends the detection limit of conventional (short tandem repeats-based) chimerism analysis from 1 to 0.01% host cells in whole blood. Read More

    Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant 2018 Apr 30. Epub 2018 Apr 30.
    Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

    Development of a quantitative PCR detecting Cunninghamella bertholletiae to help in diagnosing this rare and aggressive mucormycosis.
    Bone Marrow Transplant 2018 Apr 30. Epub 2018 Apr 30.
    Chrono-Environnement CNRS 6249 Research Team, Franche-Comté University, Besançon, France.
    Mucormycosis is an invasive mold infection, frequently fatal in immunocompromised patients. We report the case of a patient with chronic lymphocytic leukemia admitted to the hematology unit for febrile aplasia. Pulmonary lesions suggesting a fungal infection expanded/increased despite a combination of posaconazole and liposomal amphotericin B. Read More

    Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation.
    Bone Marrow Transplant 2018 Apr 29. Epub 2018 Apr 29.
    Bone Marrow Transplant Unit, Department of Hematology, Hospital Clínic of Barcelona, Barcelona, Spain.
    Autologous stem cell transplantation (PBSCT) is standard for young patients in MM and its TRM has decreased after the 2000s. Bortezomib and immunomodulatory agents (IMiDs) in MM have improved the outcome. However, they seem to boost pro-inflammatory stage increasing the incidence of engraftment syndrome (ES). Read More

    Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality.
    Bone Marrow Transplant 2018 Apr 27. Epub 2018 Apr 27.
    GRRR-OH-Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie, Paris, France.
    Outcome of patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) has improved. To investigate if this improvement can be transposed to the ICU setting, we conducted a systematic review and meta-analysis to assess short-term mortality of critically ill allo-HSCT patients admitted to the ICU and to identify prognostic factors of mortality. Public-domain electronic databases, including Medline via PubMed and the Cochrane Library were searched. Read More


    Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review.
    Bone Marrow Transplant 2018 Apr 27. Epub 2018 Apr 27.
    Division of Hematology Oncology, Department of Medicine, University of Arizona, Tucson, AZ, 85724, USA.
    Approximately 20-30% of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40-50% of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. Read More

    CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide.
    Bone Marrow Transplant 2018 Apr 27. Epub 2018 Apr 27.
    Division of Hematology and Bone Marrow Transplant, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
    The effects of graft or donor characteristics in haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PT-Cy) are largely unknown. In this multicenter retrospective study we analyzed the correlations between graft cell composition (CD34+, CD3+) and donor features on transplant outcomes in 234 patients who underwent HCT between 2010 and 2016. On multivariate analysis, the use of peripheral blood stem cells (PBSC) was associated with an increased incidence of grade 2-4 acute GVHD [HR 1. Read More

    Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
    Bone Marrow Transplant 2018 Apr 27. Epub 2018 Apr 27.
    Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
    Maintenance therapy post-autologous hematopoietic cell transplantation (AHCT) with either lenalidomide or bortezomib for multiple myeloma (MM) have separately been shown to improve progression-free survival (PFS), but have never been directly compared. We performed a retrospective study to investigate progression-free and overall survival outcomes and toxicities of lenalidomide maintenance therapy compared with bortezomib maintenance in MM patients post-AHCT. This study included 156 patients who received post-AHCT lenalidomide or bortezomib maintenance therapy for MM. Read More



    High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
    Bone Marrow Transplant 2018 Apr 19. Epub 2018 Apr 19.
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
    Transplant-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplant that can result in multi-organ failure (MOF). Patients undergoing high-dose chemotherapy with autologous stem cell transplant (aHCT) for neuroblastoma require good organ function to receive post-transplant radiation and immunotherapy. We examined TA-TMA incidence and transplant outcomes in patients with neuroblastoma receiving different transplant preparative regimens. Read More

    Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.
    Bone Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Blood & Marrow Transplant & Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
    Glucocorticoids for primary therapy of acute GVHD have limited responses. A phase I/II trial tested 4 weeks of deacetylase inhibitor panobinostat started within 48 h of glucocorticoids (1 mg/kg/day prednisone or equivalent) as primary treatment for patients with either classic acute GVHD (n = 16) or acute GVHD overlapping with chronic (n = 6). Four patients received 2. Read More

    AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
    Bone Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Chaim Sheba Medical Center, Tel-Hashomer, EBMT Paris Study Office, Israel, France.
    Acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) (3q26 AML) is a rare disease with poor prognosis and median survival of <1 year. Read More

    Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis.
    Bone Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Basic and Applied Immunology Program, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
    In the months that follow autologous hematopoietic stem cell transplantation (AHSCT), lymphopenia drives homeostatic proliferation, leading to oligoclonal expansion of residual cells. Here we evaluated how replicative senescent and exhausted cells associated with clinical outcomes of 25 systemic sclerosis (SSc) patients who underwent AHSCT. Patients were clinically monitored for skin (modified Rodnan's skin score, mRSS) and internal organ involvement and had blood samples collected before and semiannually, until 3 years post-AHSCT, for quantification of telomere length, CD8CD28 and PD-1 cells, and serum cytokines. Read More


    Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant 2018 Apr 16. Epub 2018 Apr 16.
    Department of Hematology, University Hospital Centre, Zagreb, Croatia.
    Conflicting results have been reported regarding the association between early cytomegalovirus (CMV) reactivation and relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This prompted us to evaluate the impact of CMV reactivation on outcomes of 155 consecutive adult patients transplanted in our institution. In our study, CMV reactivation did not affect cumulative incidence (CI) of relapse in patients with lymphoproliferative disorders. Read More

    Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.
    Bone Marrow Transplant 2018 Apr 16. Epub 2018 Apr 16.
    Acute Leukemia Working Party of EBMT, Paris, France.
    Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Read More

    Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting.
    Bone Marrow Transplant 2018 Apr 13. Epub 2018 Apr 13.
    Department of Oncology, Stem Cell Transplant Center, AOU Città della Salute e della Scienza, Turin, Italy.
    We evaluated the potential correlation of the hematopoietic cell transplantation comorbidity index (HCT-CI) with the risk of developing post-transplant invasive fungal infections (IFIs). Between January 2009 and March 2015, 312 consecutive patients who received a first allograft entered the study. Low/intermediate HCT-CI risk score (0-2) was observed in 172/312 (55%), whereas high HCT-CI score (≥3) was seen in 140/312 (45%). Read More

    Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study.
    Bone Marrow Transplant 2018 Apr 13. Epub 2018 Apr 13.
    Maladies du sang, CHRU de Lille, 59037, Lille, France.
    Cytomegalovirus is one of the main contributing factors to high mortality rates in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The main factors of treatment failure are both drug resistance and intolerance. In some cases, Cytotect®CP CMV-hyperimmune globulin is used as salvage therapy. Read More

    Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.
    Bone Marrow Transplant 2018 Mar 27. Epub 2018 Mar 27.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    Receipt of hematopoietic cell transplantation (HCT) can improve overall survival in older patients with intermediate or high-risk acute myeloid leukemia (AML); however, utilization of HCT is poor. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients. We utilized the National Cancer Database to determine receipt of HCT in older patients (61-75 years) with intermediate or high-risk AML reported between 2003 and 2012. Read More

    Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant 2018 Mar 26. Epub 2018 Mar 26.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
    We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24-230). Read More


    Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.
    Bone Marrow Transplant 2018 Mar 21. Epub 2018 Mar 21.
    Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul. St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
    Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The reconditioning regimen (TNI-750/ATG) consisted of a single dose of total nodal irradiation (TNI, 750 cGy) and antithymocyte globulin (ATG; Thymoglobulin, 1. Read More

    Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD.
    Bone Marrow Transplant 2018 Mar 21. Epub 2018 Mar 21.
    Michael Cuccione Childhood Cancer Research Program, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
    Toll-like receptor-9 (TLR9) responsive B cells have previously been associated with the onset of extensive chronic graft-versus-host disease (cGvHD). We hypothesized that the onset of cGvHD associated with a higher level of plasma-free mitochondrial DNA (mtDNA), a putative TLR9 agonist. Plasma cell-free mtDNA levels were measured in 39 adult patients post-HSCT with and without cGvHD. Read More

    1 OF 223